Aurora-A kinase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “Aurora-A kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Aurora-A kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Aurora-A kinase inhibitors: Overview
The Aurora kinases are composed of three highly conserved serine/threonine kinases: Aurora A, B, and C that regulate mitotic and meiotic processes. Aurora-A plays an important role in centrosome maturation, spindle assembly, meiotic maturation, and metaphase I spindle orientation. Aurora A mRNA/protein expression and kinase activity are cell-cycle regulated, with basal level at interphase and expression/activity dramatically increased from late G2 to telophase in mitosis. Aurora A is a mitotic kinase whose depletion primarily leads to mitotic spindle formation defects and consequently prometaphase arrest in human cancer cell lines, evidenced by the increase of histone H3 Ser10 phosphorylation as a mitotic marker. Aurora kinase has emerged as one of the important cell cycle regulator in cancer genesis. Therapeutic inhibition of Aurora kinase showed great promise as probable anticancer regimen.
Report Highlights
This segment of the Aurora-A kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aurora-A kinase inhibitors Emerging Drugs
Further product details are provided in the report……..
Aurora-A kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Aurora-A kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Aurora-A kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aurora-A kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aurora-A kinase inhibitors drugs.
Aurora-A kinase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Aurora-A kinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Aurora-A kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Aurora-A kinase inhibitors: Overview
The Aurora kinases are composed of three highly conserved serine/threonine kinases: Aurora A, B, and C that regulate mitotic and meiotic processes. Aurora-A plays an important role in centrosome maturation, spindle assembly, meiotic maturation, and metaphase I spindle orientation. Aurora A mRNA/protein expression and kinase activity are cell-cycle regulated, with basal level at interphase and expression/activity dramatically increased from late G2 to telophase in mitosis. Aurora A is a mitotic kinase whose depletion primarily leads to mitotic spindle formation defects and consequently prometaphase arrest in human cancer cell lines, evidenced by the increase of histone H3 Ser10 phosphorylation as a mitotic marker. Aurora kinase has emerged as one of the important cell cycle regulator in cancer genesis. Therapeutic inhibition of Aurora kinase showed great promise as probable anticancer regimen.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Aurora-A kinase inhibitors R&D. The therapies under development are focused on novel approaches for Aurora-A kinase inhibitors.
This segment of the Aurora-A kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aurora-A kinase inhibitors Emerging Drugs
- LY-3295668: Eli Lilly and Company
- TT-00420: TransThera Biosciences
Further product details are provided in the report……..
Aurora-A kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Aurora-A kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Aurora-A kinase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Aurora-A kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aurora-A kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aurora-A kinase inhibitors drugs.
Aurora-A kinase inhibitors Report Insights
- Aurora-A kinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Aurora-A kinase inhibitors drugs?
- How many Aurora-A kinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Aurora-A kinase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aurora-A kinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Aurora-A kinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- TransThera Biosciences
- Eli Lilly and Company
- Takeda Oncology
- Wigen Biomedicine
- TT-00420
- LY-3295668
- Alisertib
- WJ-05129
Introduction
Executive Summary
Aurora-A kinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Aurora-A kinase inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Aurora-A kinase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Aurora-A kinase inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Registered)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
LY-3295668: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
WJ-05129: Wigen Biomedicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Aurora-A kinase inhibitors Key Companies
Aurora-A kinase inhibitors Key Products
Aurora-A kinase inhibitors- Unmet Needs
Aurora-A kinase inhibitors- Market Drivers and Barriers
Aurora-A kinase inhibitors- Future Perspectives and Conclusion
Aurora-A kinase inhibitors Analyst Views
Aurora-A kinase inhibitors Key Companies
Appendix
Executive Summary
Aurora-A kinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Aurora-A kinase inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Aurora-A kinase inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Aurora-A kinase inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Registered)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
LY-3295668: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
WJ-05129: Wigen Biomedicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Aurora-A kinase inhibitors Key Companies
Aurora-A kinase inhibitors Key Products
Aurora-A kinase inhibitors- Unmet Needs
Aurora-A kinase inhibitors- Market Drivers and Barriers
Aurora-A kinase inhibitors- Future Perspectives and Conclusion
Aurora-A kinase inhibitors Analyst Views
Aurora-A kinase inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Aurora-A kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Aurora-A kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Aurora-A kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Aurora-A kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
